Everfront Biotech Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Taipei Taiwan (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2018
NCT03651349
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Everfront Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

ef-009 (1 trial)

Drugs in Phase 1 Trials (1)

(Z)-n-butylidenephthalide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 1)

Motor Neuron Disease (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2